Avinoam Shiran

Avinoam Shiran

Auto-generated profile, based on publicly available information

Avinoam Shiran

Department of Cardiology, Carmel Medical Center, Haifa, Israel

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in JACC
Verified
Journal Article
Closed access
ASAvinoam Shiran
Avinoam Shiran
ASAlex Sagie
Alex Sagie

18 August 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
SAShimrit Avraham
Shimrit Avraham
SASoraya Abu-Sharki
Soraya Abu-Sharki
RSRona Shofti
Rona Shofti
THTali Haas
Tali Haas
BKBen Korin
Ben Korin
AAAmi Aronheim
Ami Aronheim
Background: Recent evidence suggests that cancer and cardiovascular diseases are associated. Chemotherapy drugs are known to result in cardiotoxicity, and studies have shown that heart failure and stress correlate with poor cancer prognosis. However, whether cardiac remodeling in the absence of heart failure is sufficient to promote cancer is unknown. Methods: To investigate the effect of early cardiac remodeling on tumor growth and metastasis colonization, we used transverse aortic constriction (TAC), a model for pressure overload–induced cardiac hypertrophy, and followed it by cancer cell implantation. Results: TAC-operated mice developed larger primary tumors with a higher proliferation rate and displayed more metastatic lesions compared with controls. Serum derived from TAC-operated mice potentiated cancer cell proliferation in vitro, suggesting the existence of secreted tumor-promoting factors. Using RNA-sequencing data, we identified elevated mRNA levels of periostin in the hearts of TAC-operated mice. Periostin levels were also found to be high in the serum after TAC. Depletion of periostin from the serum abrogated the proliferation of cancer cells; conversely, the addition of periostin enhanced cancer cell proliferation in vitro. This is the first study to show that early cardiac remodeling nurtures tumor growth and metastasis and therefore promotes cancer progression. Conclusions: Our study highlights the importance of early diagnosis and treatment of cardiac remodeling because it may attenuate cancer progression and improve cancer outcome.

11 February 2016 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
DMDiego Medvedofsky
Diego Medvedofsky
DADoron Aronson
Doron Aronson
MGMardi Gomberg-Maitland
Mardi Gomberg-Maitland
VTVasiliki Thomeas
Vasiliki Thomeas
SRStuart Rich
Stuart Rich
ASAvinoam Shiran
Avinoam Shiran
Aims The aim of this study was to determine the mechanism of tricuspid regurgitation (TR) progression in pulmonary arterial hypertension (PAH) and its effect on survival. Methods and results We studied 88 patients with PAH and functional TR (mean pulmonary artery pressure 49 ± 14 mmHg; 43% idiopathic PAH) who had serial echocardiograms. TR progression (n = 35) was defined as ≤mild TR on Echo 1 and ≥moderate TR on Echo 2. TR regression (n = 17) was defined as ≥moderate TR on Echo 1 and ≤mild TR on Echo 2. Stable TR (n = 36) was defined as ≤mild TR on both echoes. TR progression was associated with an increase in pulmonary artery systolic pressure (PASP, 62 ± 22–92 ± 23 mmHg, P < 0.0001), right ventricular (RV) enlargement, mainly at mid-ventricular level, increased RV sphericity (6.1 ± 1.7–6.9 ± 1.8, P = 0.004), tricuspid annular (TA) dilatation (4.0 ± 0.7–4.6 ± 0.7 cm, P < 0.0001), and increased tricuspid valve (TV) tenting area (2.0 ± 0.7–2.5 ± 1.0 cm2, P = 0.0003). TR regression was associated with a reduction in PASP (84 ± 15–55 ± 18 mmHg, P < 0.0001), reverse RV remodelling with a reduction in RV sphericity (6.3 ± 1.4–5.5 ± 1.0, P = 0.02), and a reduction in TA size (4.1 ± 0.7–3.6 ± 0.7 cm, P = 0.02) and TV tenting (2.1 ± 0.7–1.3 ± 0.5 cm2, P = 0.0002). TR progression was associated with all-cause mortality (log-rank P = 0.0007). Conclusion In PAH, TR progression was associated with worsening pulmonary hypertension and adverse RV and TV apparatus remodelling. TR progression is associated with poor outcome in PAH.

1 March 2014 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ASAvinoam Shiran
Avinoam Shiran
RNRiham Najjar
Riham Najjar
SASalim Adawi
Salim Adawi
DADoron Aronson
Doron Aronson

28 May 2022 in The American Journal of Medicine
Verified
Journal Article
Closed access
TGTamer Ghanayim
Tamer Ghanayim
LLLior Lupu
Lior Lupu
SNSivan Naveh
Sivan Naveh
NBNoa Bachner-Hinenzon
Noa Bachner-Hinenzon
DADoron Adler
Doron Adler
ASAvinoam Shiran
Avinoam Shiran

19 March 2012 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
IAIhab Asmer
Ihab Asmer
SASalim Adawi
Salim Adawi
MGMajdi Ganaeem
Majdi Ganaeem
JSJeryes Shehadeh
Jeryes Shehadeh
ASAvinoam Shiran
Avinoam Shiran
Aims Right ventricular (RV) function has important prognostic and therapeutic implications. Assessment of RV function using echocardiography is challenging. The aim of this study was to evaluate a new parameter of RV function, right ventricular outflow tract systolic excursion (RVOT_SE). Methods and results RVOT\_SE was measured using M-Mode echocardiography from the parasternal short-axis view at the level of the aortic valve, and was defined as the systolic excursion of the RVOT anterior wall. RVOT\_SE was measured in 50 patients (age 64 ± 18 years, 28 males) with normal RV function [RV fractional area change (FAC) ≥35% and tricuspid annular plane systolic excursion (TAPSE) ≥1.6 cm] and 40 patients (age 68 ± 12 years, 35 males) with reduced RV function (RV FAC <35% and TAPSE <1.6 cm). R.V FAC was 46 ± 7% in the normal RV group and 22 ± 5% in the reduced RV group ( P < 0.0001). TAPSE was 2.2 ± 0.4 cm in the normal RV group and 1.0 ± 0.2 cm in the reduced RV group ( P < 0.0001). RVOT\_SE was 9.6 ± 1.5 mm in the normal RV group and 1.7 ± 1.1 mm in the reduced RV group ( P < 0.0001). RVOT\_SE <6 mm identified patients with reduced RV function with 100% sensitivity and 100% specificity. Survival at 1 year was 63% in patients with RVOT\_SE <6 mm and 84% in patients with RVOT\_SE ≥6 mm, P = 0.004. Conclusion RVOT_SE is a novel, simple, and promising parameter for assessing RV function, and it is associated with poor survival.